France
Nanobiotix, founded in 2003, is a pioneering nanotherapeutics company that focuses on developing innovative solutions to significantly improve patient outcomes in the field of oncology. With the slogan "Building new therapies atom by atom," Nanobiotix embodies its philosophy of leveraging physical-based approaches to address high unmet medical needs.
The company’s flagship product, NBTXR3 (JNJ-1900), aims to enhance the efficacy of radiotherapy in treating cancer by increasing the tumor-killing effect while minimizing damage to surrounding healthy tissues. This product aligns with Nanobiotix's strategy to target patients undergoing radiotherapy as a part of their treatment, representing a substantial market opportunity in oncology.
In addition to its pioneering product, Nanobiotix is also advancing the Curadigm Nanoprimer Platform, designed to optimize drug bioavailability and efficacy across various therapeutic classes through enhanced systemic delivery. This demonstrates the company's commitment to innovation and diversification.
Headquartered in France, Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP) and on the Nasdaq Global Select Market (Nasdaq: NBTX). The company has gained recognition and backing from notable investors, with its last investment of €4.60M in post-IPO equity coming from Johnson & Johnson Innovation – JJDC in 04 December 2023, showcasing confidence in its innovative approaches.
Overall, Nanobiotix's pioneering nanotechnology-based therapies and strategic global development approach position it as a compelling player in the biotechnology and healthcare industries, promising substantial impact and growth potential.
